VALNEVA: US DEPARTMENT OF DEFENSE WAIVES OPTION TO BUY IXIARO
PARIS (Archyde.com) – Valneva said on Thursday that the U.S. Department of Defense had decided not to exercise the second annual contract option for the supply of its Japanese encephalitis vaccine, Ixiaro.
The French laboratory indicates that the United States Department of Defense considers that its supplies of Ixiaro are sufficient to meet its needs.
According to Valneva, the decision not to exercise the second supply option has no impact on its financial forecast for 2022.
The group specifies that this option had a nominal value of 36 million dollars for 250,000 doses.
“The ‘DoD’ (US Department of Defense-Editor’s note) considers that its existing supply levels of Ixiaro are sufficient to meet its current needs”, explains the company in a press release.
(Written by Matthieu Protard)